Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018’, provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM)

- The report reviews pipeline therapeutics for Inclusion Body Myositis (IBM) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Inclusion Body Myositis (IBM) therapeutics and enlists all their major and minor projects

- The report assesses Inclusion Body Myositis (IBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Inclusion Body Myositis (IBM)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Kv1.3 Therapeutics

Milo Biotechnology LLC

Nobelpharma Co Ltd

Orphazyme A/S

Ultragenyx Pharmaceutical Inc

Kv1.3 Therapeutics

Milo Biotechnology LLC

Nobelpharma Co Ltd

Orphazyme A/S

Ultragenyx Pharmaceutical Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Inclusion Body Myositis (IBM) - Overview

Inclusion Body Myositis (IBM) - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Inclusion Body Myositis (IBM) - Overview

Inclusion Body Myositis (IBM) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Inclusion Body Myositis (IBM) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development

Kv1.3 Therapeutics

Milo Biotechnology LLC

Nobelpharma Co Ltd

Orphazyme A/S

Ultragenyx Pharmaceutical Inc

Inclusion Body Myositis (IBM) - Drug Profiles

AAV1-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aceneuramic acid ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALZ-1903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arimoclomol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEXM-74 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UX-001P - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Inclusion Body Myositis (IBM) - Dormant Projects

Inclusion Body Myositis (IBM) - Discontinued Products

Inclusion Body Myositis (IBM) - Product Development Milestones

Featured News & Press Releases

Apr 25, 2018: New Data Supports Dalazatide from Kv 1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis

Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union

Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy

Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency

May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy

Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy

Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society

Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting

Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy

Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress

Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy

Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Inclusion Body Myositis (IBM), H2 2018

Number of Products under Development by Companies, H2 2018

Products ...

List of Tables

Number of Products under Development for Inclusion Body Myositis (IBM), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Inclusion Body Myositis (IBM) - Pipeline by Kv1.3 Therapeutics, H2 2018

Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, H2 2018

Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, H2 2018

Inclusion Body Myositis (IBM) - Pipeline by Orphazyme A/S, H2 2018

Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018

Inclusion Body Myositis (IBM) - Dormant Projects, H2 2018

Inclusion Body Myositis (IBM) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Inclusion Body Myositis (IBM), H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Figures

Number of Products under Development for Inclusion Body Myositis (IBM), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports